文献速递前列腺癌

混合现实导航系统在高危前列腺癌机器人辅助根治性前列腺切除术中的应用:倾向性评分匹配队列研究

The application of mixed reality navigation system in robot-assisted radical prostatectomy for high-risk prostate cancer: a propensity score‑matched cohort study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-07-25

该回顾性倾向性评分匹配队列研究纳入147例高危前列腺癌患者,比较混合现实辅助机器人辅助根治性前列腺切除术(MR-RARP)与标准RARP的围手术期、功能及肿瘤学结局,匹配后每组57例。结果显示MR-RARP组神经保留率更高、切缘阳性率更低,早期控尿和勃起功能恢复更优,而生化复发无显著差异。

要点

  • MR导航提高神经保留率并降低切缘阳性率。
  • MR导航改善术后早期控尿和勃起功能恢复。
  • MR导航不损害肿瘤学安全,生化复发无差异。

核心结论

  • 实时术中MR导航增强手术精度,促进神经保留技术,优化早期控尿和勃起功能恢复,且不损害肿瘤学安全。

研究设计与样本

  • 回顾性倾向性评分匹配队列研究,纳入2021年7月至2023年11月基于D'Amico风险标准的高危前列腺癌患者147例,匹配后每组57例。

主要发现

  • MR-RARP组神经保留率78.9% vs 54.4%(P=0.021),切缘阳性率10.5% vs 26.3%(P=0.030)。
  • MR-RARP组控尿恢复率在拔管时40.4% vs 22.8%(P=0.044)、1个月61.4% vs 38.6%(P=0.015)、3个月73.7% vs 47.4%(P=0.004),6个月和12个月无显著差异。
  • MR-RARP组勃起功能率在1个月42.1% vs 21.1%(P=0.016)、3个月57.9% vs 36.8%(P=0.024),6个月和12个月无显著差异。
  • 中位随访28个月,无生化复发生存无显著差异(P=0.295)。
  • 多因素分析确认MR导航是切缘阳性、控尿和勃起功能恢复的独立预测因素(均P<0.05),统计功效分析显示功效为0.847。

临床怎么用

  • 对于高危前列腺癌患者,在机器人辅助根治性前列腺切除术中可考虑使用MR导航系统,以提升神经保留率和早期功能恢复。

局限性

  • 回顾性研究设计,样本量有限,随访时间较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aims to evaluate the efficacy and advantages of MR navigation system in robot-assisted radical prostatectomy (RARP) for high-risk prostate cancer (PCa). METHODS: We retrospectively studied 147 patients with high-risk PCa based on D'Amico risk criteria from July 2021 to November 2023. All patients chose MR-assisted RARP (MR-RARP) or standard RARP (S-RARP) after receiving comprehensive counseling on the benefits and risks of both procedures. After propensity score-matching, 57 patients were included in each group. Perioperative, functional and oncological outcomes were compared. Logistic and Cox regression models were used to identify predictors of positive surgical margin (PSM), biochemical recurrence (BCR), continence and potency recovery. RESULTS: The MR-RARP group had higher nerve-sparing (NS) rates (78.9% vs 54.4%, P = 0.021) and lower PSM rates (10.5% vs 26.3%, P = 0.030). Continence recovery rates were higher in the MR-RARP group at catheter removal (40.4% vs 22.8%, P = 0.044), 1 month (61.4% vs 38.6%, P = 0.015) and 3 months (73.7% vs 47.4%, P = 0.004), with no significant differences at 6 months (82.5% vs 73.7%, P = 0.258) and 12 months (93.0% vs 87.7%, P = 0.341). Furthermore, the MR-RARP group demonstrated higher potency rates at 1 month (42.1% vs 21.1%, P = 0.016) and 3 months (57.9% vs 36.8%, P = 0.024), whereas outcomes were comparable at 6 months (66.7% vs 56.1%, P = 0.248) and 12 months (77.2% vs 66.7%, P = 0.211). With a median follow-up of 28 months, BCR-free survival showed no significant differences (P = 0.295). Multivariate analyses confirmed MR navigation as an independent predictor of PSM, continence, and potency recovery (all P < 0.05). Statistical power analysis indicated a power of 0.847. CONCLUSIONS: Real-time intraoperative MR navigation enhances surgical precision, facilitates NS techniques, and optimizes early continence and potency recovery without compromising oncological safety.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Liu W, Zhou S, Yu X, et al. The application of mixed reality navigation system in robot-assisted radical prostatectomy for high-risk prostate cancer: a propensity score‑matched cohort study. Prostate Cancer Prostatic Dis. 2025. PMID: 40715667. doi:10.1038/s41391-025-01003-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。